NDC product
ezetimibe and simvastatin
NDC 68462-321 · Glenmark Pharmaceuticals Inc., USA
Key facts
| Product NDC | 68462-321 |
|---|---|
| Proprietary name | ezetimibe and simvastatin |
| Nonproprietary name | ezetimibe and simvastatin |
| Substances | EZETIMIBE, SIMVASTATIN |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Glenmark Pharmaceuticals Inc., USA |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA208699 |
| Pharmacologic classes | Decreased Cholesterol Absorption [PE], Dietary Cholesterol Absorption Inhibitor [EPC], HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA] |
| Marketing start | Jun 27, 2019 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: